Management of Perimenopausal Women with Heterozygous HFE Mutation

Introduction to HFE Mutation Management

The European Association for the Study of the Liver guidelines state that heterozygosity for a single HFE mutation is insufficient to cause hemochromatosis and does not require phlebotomy, as heterozygotes rarely develop clinically significant iron overload 1, 2
The American Association for the Study of Liver Diseases recommends that patients with heterozygous HFE mutations and normal iron parameters do not require treatment, but rather annual monitoring of iron studies 1, 4

Patients with heterozygous HFE mutations and normal iron panels (transferrin saturation and ferritin within normal limits) do not require treatment, but rather annual monitoring 2, 1
Perimenopausal status provides additional protection against iron accumulation due to menstrual blood loss, which prevents iron overload in women with heterozygous HFE mutations 3

Annual monitoring of transferrin saturation and serum ferritin is recommended for patients with heterozygous HFE mutations, with thresholds for further evaluation being >45% for transferrin saturation and >200 μg/L for serum ferritin in women 1, 2, 5
If both parameters remain normal, continue annual monitoring indefinitely 1, 2
If either parameter becomes elevated, investigate for secondary causes of iron overload before attributing to HFE heterozygosity, including chronic alcohol consumption, non-alcoholic fatty liver disease, and chronic liver disease 1, 2, 5

Maintain a healthy lifestyle to prevent secondary iron accumulation, including avoiding excessive alcohol consumption and maintaining a healthy weight 1, 5
Avoid iron supplementation unless documented iron deficiency develops, and avoid vitamin C supplements if iron overload develops 2

First-degree relatives of patients with heterozygous HFE mutations should be offered genetic testing and iron studies, although this is primarily relevant for homozygous patients 4, 3, 2